Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-α-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 3, 2011, Pages 1013-1022

  Kim, Jong Eun ^a   Son, Joe Eun ^a   Jang, Young Jin ^a   Lee, Dong Eun ^a   Kang, Nam Joo ^c   Jung, Sung Keun ^a   Heo, Yong Seok ^b   Lee, Ki Won ^a   Lee, Hyong Joo ^a  

^a Seoul National University   (South Korea)

^b Konkuk University   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN P90; PROTEIN SERINE THREONINE KINASE; S6 KINASE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROGRESSION LOCUS 2 PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; DOSE RESPONSE; DOWN REGULATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPIDERMIS CELL; HUMAN; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; UPREGULATION;

ANIMALS; BINDING, COMPETITIVE; BLOTTING, WESTERN; CELL SURVIVAL; CYCLOOXYGENASE 2; EPIDERMIS; EXPECTORANTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE SILENCING; IMMUNOPRECIPITATION; LUCIFERASES; LUTEOLIN; MAP KINASE KINASE KINASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; NF-KAPPA B; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052156984     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179200     Document Type: Article

References (39)

1. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, and Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:1605-1621. (Pubitemid 44666739)
2. Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Rémésy C, Chap H, and Payrastre B (1997) Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 53:1649-1657. (Pubitemid 27356094)
3. Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, and Balkwill FR (2004) Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development. Oncogene 23:1902-1910. (Pubitemid 38445416)
4. Balkwill F (2006) TNF-α in promotion and progression of cancer. Cancer Metastasis Rev 25:409-416.
5. Balkwill F and Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545. (Pubitemid 32173595)
6. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, Takeshita T, Flavell RA, and Davis RJ (2003) Mechanism of p38 MAP kinase activation in vivo. Genes Dev 17:1969-1978. (Pubitemid 36999324)
7. Chiariello M, Marinissen MJ, and Gutkind JS (2000) Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol 20:1747-1758. (Pubitemid 30100193)
8. Cho J and Tsichlis PN (2005) Phosphorylation at Thr-290 regulates Tpl2 binding to NF-κB1/p105 and Tpl2 activation and degradation by lipopolysaccharide. Proc Natl Acad Sci USA 102:2350-2355. (Pubitemid 40279379)
9. Choi HS, Kang BS, Shim JH, Cho YY, Choi BY, Bode AM, and Dong Z (2008) Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of c-fos transcriptional activity. FASEB J 22:113-126.
10. Choi KH, Kim JE, Song NR, Son JE, Hwang MK, Byun S, Kim JH, Lee KW, and Lee HJ (2010) Phosphoinositide 3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovasc Res 85:836-844.
11. Christoforidou AV, Papadaki HA, Margioris AN, Eliopoulos GD, and Tsatsanis C (2004) Expression of the Tpl2/Cot oncogene in human T-cell neoplasias. Mol Cancer 3:34.
12. Chun KS and Surh YJ (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 68:1089-1100.
13. Clark AM, Reynolds SH, Anderson M, and Wiest JS (2004) Mutational activation of the MAP3K8 protooncogene in lung cancer. Genes Chromosomes Cancer 41:99-108. (Pubitemid 39096735)
14. Das S, Cho J, Lambertz I, Kelliher MA, Eliopoulos AG, Du K, and Tsichlis PN (2005) Tpl2/Cot Signals Activate ERK, JNK, and NF-κB in a cell-type and stimulus-specific manner. J Biol Chem 280:23748-23757.
15. Di Carlo G, Mascolo N, Izzo AA, and Capasso F (1999) Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci 65:337-353. (Pubitemid 29325278)
16. Eliopoulos AG, Das S, and Tsichlis PN (2006) The tyrosine kinase Syk regulates TPL2 activation signals. J Biol Chem 281:1371-1380.
17. Erny KM, Peli J, Lambert JF, Muller V, and Diggelmann H (1996) Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis. Oncogene 13:2015-2020. (Pubitemid 26397462)
18. Ferriola PC, Cody V, and Middleton E Jr (1989) Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem Pharmacol 38:1617-1624. (Pubitemid 19120080)
19. Harrington LS, Findlay GM, and Lamb RF (2005) Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30:35-42. (Pubitemid 40093739)
20. Harris RE (2007) Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 42:93-126.
21. Huang C, Li J, Ma WY, and Dong Z (1999) JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-α but not by 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem 274:29672-29676.
22. Jaeschke A, Karasarides M, Ventura JJ, Ehrhardt A, Zhang C, Flavell RA, Shokat KM, and Davis RJ (2006) JNK2 is a positive regulator of the cJun transcription factor. Mol Cell 23:899-911. (Pubitemid 44344520)
23. Kikuchi T, Yoshikai Y, Miyoshi J, Katsuki M, Musikacharoen T, Mitani A, Tanaka S, Noguchi T, and Matsuguchi T (2003) Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. J Dent Res 82:546-550. (Pubitemid 41756888)
24. Kim JE, Kwon JY, Lee DE, Kang NJ, Heo YS, Lee KW, and Lee HJ (2009) MKK4 is a novel target for the inhibition of tumor necrosis factor-α-induced vascular endothelial growth factor expression by myricetin. Biochem Pharmacol 77:412-421.
25. Kim JE, Kwon JY, Seo SK, Son JE, Jung SK, Min SY, Hwang MK, Heo YS, Lee KW, and Lee HJ (2010) Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1. Biochem Pharmacol 79:1473-1482.
26. Kim JE, Lee DE, Lee KW, Son JE, Seo SK, Li J, Jung SK, Heo YS, Mottamal M, Bode AM, et al. (2011) Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K. Cancer Prev Res (Phila) 4:582-591.
27. Knight B, Yeoh GC, Husk KL, Ly T, Abraham LJ, Yu C, Rhim JA, and Fausto N (2000) Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 192:1809-1818. (Pubitemid 32049773)
28. Kontoyiannis D, Boulougouris G, Manoloukos M, Armaka M, Apostolaki M, Pizarro T, Kotlyarov A, Forster I, Flavell R, Gaestel M, et al. (2002) Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 196:1563-1574. (Pubitemid 36026468)
29. Kwon JY, Lee KW, Kim JE, Jung SK, Kang NJ, Hwang MK, Heo YS, Bode AM, Dong Z, and Lee HJ (2009) Delphinidin suppresses ultraviolet B-induced cyclooxygenases-2 expression through inhibition of MAPKK4 and PI-3 kinase. Carcinogenesis 30:1932-1940.
30. Lee KM, Lee KW, Bode AM, Lee HJ, and Dong Z (2009) Tpl2 is a key mediator of arsenite-induced signal transduction. Cancer Res 69:8043-8049.
31. Lin Y, Shi R, Wang X, and Shen HM (2008) Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 8:634-646.
32. Middleton E Jr, Kandaswami C, and Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673-751.
33. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, et al. (1999) Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med 5:828-831. (Pubitemid 29318619)
34. Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, Chalfant CE, Obeid LM, and Hannun YA (2003) The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-α. FASEB J 17:1411-1421. (Pubitemid 36939148)
35. Seelinger G, Merfort I, and Schempp CM (2008) Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med 74:1667-1677.
36. Sourvinos G, Tsatsanis C, and Spandidos DA (1999) Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 18:4968-4973. (Pubitemid 29425303)
37. Vogt PK and Kang S (2006) Kinase inhibitors: vice becomes virtue. Cancer Cell 9:327-328. (Pubitemid 43668736)
38. Vougioukalaki M, Kanellis DC, Gkouskou K, and Eliopoulos AG (2011) Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett 304:80-89.
39. Yan Y, Li J, Ouyang W, Ma Q, Hu Y, Zhang D, Ding J, Qu Q, Subbaramaiah K, and Huang C (2006) NFAT3 is specifically required for TNF-α-induced cyclooxygenase-2 (COX-2) expression and transformation of Cl41 cells. J Cell Sci 119:2985-2994. (Pubitemid 44177877)